PP
GBT

Paloma Partners’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Paloma Partners’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,014
Closed -$408K – 2211
2021
Q3 		$408K Buy
+16,014
New +$471K 0.01% 630
2021
Q1 		– Sell
-15,500
Closed -$671K – 2452
2020
Q4 		$671K Sell
15,500
-36,978
-70% -$1.82M 0.02% 758
2020
Q3 		$2.89M Sell
52,478
-16,451
-24% -$1.05M 0.07% 271
2020
Q2 		$4.35M Buy
+68,929
New +$4.73M 0.08% 340

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Paloma Partners's GBT Position: Q4 2021 in Review

Paloma Partners sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2021, closing a stake of 16,014 shares — an estimated $408K sold.

Paloma Partners first reported a position in GBT in Q2 2020 and held it in 4 quarters. The position peaked at $4.35M in Q2 2020. 206 funds tracked by Wall St. Rank hold GBT as of Q4 2021.

  • Paloma Partners reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Paloma Partners sold 16,014 Global Blood Therapeutics, Inc. shares in Q4 2021, an estimated $408K.
  • Paloma Partners first reported a position in Global Blood Therapeutics, Inc. in Q2 2020 and held it in 4 quarters.
  • Paloma Partners's Global Blood Therapeutics, Inc. position peaked at $4.35M in Q2 2020.
  • 206 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2021.

Based on Paloma Partners's 13F filing for Q4 2021, filed 14 Feb 2022.